Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

SRR1330498

GTEX

8a4d784c-d2da-5439-b81d-3bf4ccd10166

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
—
subtype
—
cancer_type
GTEX
sex
Female

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.414
  • INTERFERON_ALPHA_RESPONSE+0.390
  • CHOLESTEROL_HOMEOSTASIS+0.369
  • MYOGENESIS+0.360
  • INTERFERON_GAMMA_RESPONSE+0.358
  • ANGIOGENESIS+0.357
  • COAGULATION+0.336
  • IL6_JAK_STAT3_SIGNALING+0.323
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.303
  • INFLAMMATORY_RESPONSE+0.303

Top 10 suppressed

  • MYC_TARGETS_V2-0.438
  • HEDGEHOG_SIGNALING-0.352
  • OXIDATIVE_PHOSPHORYLATION-0.312
  • UNFOLDED_PROTEIN_RESPONSE-0.312
  • E2F_TARGETS-0.297
  • G2M_CHECKPOINT-0.284
  • DNA_REPAIR-0.258
  • MITOTIC_SPINDLE-0.210
  • WNT_BETA_CATENIN_SIGNALING-0.201
  • NOTCH_SIGNALING-0.188

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR615731
brain-umap@2
GTEX—0.917
2SRR1416889
brain-umap@2
GTEX—0.909
3SRR615934
brain-umap@2
GTEX—0.896
4SRR1387989
brain-umap@2
GTEX—0.896
5SRR1079168
brain-umap@2
GTEX—0.890
6SRR665241
brain-umap@2
GTEX—0.887
7SRR1340133
brain-umap@2
GTEX—0.885
8SRR1475675
brain-umap@2
GTEX—0.884
9SRR1325401
brain-umap@2
GTEX—0.881
10SRR661723
brain-umap@2
GTEX—0.876

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.414Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.390Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.369Remibrutinib— uncovered
MYOGENESIS0.360Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.358Idelalisib— uncovered
ANGIOGENESIS0.357Remibrutinib— uncovered
COAGULATION0.336Binimetinib— uncovered
IL6_JAK_STAT3_SIGNALING0.323Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.303Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.303Idelalisib— uncovered
COMPLEMENT0.282Inavolisib— uncovered
APOPTOSIS0.273Idelalisib— uncovered
KRAS_SIGNALING_UP0.257Inavolisib— uncovered
IL2_STAT5_SIGNALING0.247Idelalisib— uncovered
BILE_ACID_METABOLISM0.234Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.210Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.199Inavolisib— uncovered
FATTY_ACID_METABOLISM0.165Inavolisib— uncovered
PANCREAS_BETA_CELLS0.152Cobimetinib— uncovered
KRAS_SIGNALING_DN0.146Remibrutinib— uncovered